Authors: James O. Lindsay,1 David T. Rubin,2 Nicholas Scalzo,3 Joana Torres4
1. Barts and the London School of Medicine and Dentistry, UK
2. Inflammatory Bowel Disease Center, University of Chicago Medicine, Illinois, USA
3. Icahn School of Medicine at Mount Sinai, New York, USA
4. Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal
Disclosure: Lindsay has received consulting and/or speaker fees from AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Engitix, Ferring, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, MSD, Napp, Orchard Therapeutics, Pfizer, Shire, and Takeda; and investigator-led research grants from AbbVie, Gilead Sciences, and Takeda. Rubin has received consulting and/or speaker fees from AbbVie, AltruBio, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chronicles, ClostraBio, Connect BioPharma, EcoR1, Eli Lilly, Genentech/Roche, Gilead Sciences, Iterative Health, Janssen, Kaleido Biosciences, Pfizer, Prometheus Biosciences, Reistone, Seres Therapeutics, Syneos, Takeda, Target RWE, and Trellus Health; and grant/research support from Takeda. Nicholas Scalzo reported no conflicts of interest. Torres has received consulting and/or speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Sandoz; and grants from Abbvie and Janssen.
Acknowledgements: Writing assistance was provided by Nicola Humphry, Nottingham, UK
Disclaimer: The opinions expressed in this article belong solely to the authors of the posters.
Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features, and for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Ozanimod® is subject to additional monitoring. This will allow quick identification of new safety information.
Prescribing information for HCPs in the UK can be found here.
Prescribing information for HCPs in Ireland can be found here.
Adverse events should be reported. Reporting forms and information can be found via: Great Britain & Northern Ireland – The Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store; Ireland – HPRA Pharmacovigilance at www.hpra.ie
Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or 08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland).
Support: The publication of this article was funded by Bristol Myers Squibb.
Citation: EMJ. 2025;10[1]:16-25. https://doi.org/10.33590/emj/LDHY2142
Keywords: Long-term safety, ozanimod, real-world evidence, S1P receptor modulator, True North, ulcerative colitis.
This article has now been retracted and a retraction statement has been published.
Retraction: Ozanimod▼ in Ulcerative Colitis: Key New Data
